On today’s episode of Full Court Finance here at Zacks, we dive into everything investors need to know about Apple (AAPL - Free Report) and Microsoft (MSFT - Free Report) stock to help figure out if either tech giant is worth buying heading into quarterly earnings.
The Dow, S&P 500, and Nasdaq all tumbled Monday as fears about the coronavirus grow. Worries about the continued spread of the virus, which has already killed at least 80 people, could hover over the markets for some time.
But this doesn’t change the fact that this week features earnings reports from some of the biggest tech companies in the world, including Amazon (AMZN - Free Report) , Facebook , and the two $1 trillion market cap giants we discuss today.
Apple and Microsoft are both market movers that have soared over the last year. Both companies have also started to expand newer businesses. Apple’s services unit now features everything from its app store to its Netflix (NFLX - Free Report) challenger Apple TV+. Meanwhile, Microsoft has become one of the biggest cloud computing firms.
Apple is set to report its quarterly financial results after the closing bell on Tuesday, with MSFT due out Wednesday. Now the question for investors is what to do with both stocks, as their valuations continue to stretch.
Breakout Biotech Stocks with Triple-Digit Profit PotentialThe biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
On today’s episode of Full Court Finance here at Zacks, we dive into everything investors need to know about Apple (AAPL - Free Report) and Microsoft (MSFT - Free Report) stock to help figure out if either tech giant is worth buying heading into quarterly earnings.
The Dow, S&P 500, and Nasdaq all tumbled Monday as fears about the coronavirus grow. Worries about the continued spread of the virus, which has already killed at least 80 people, could hover over the markets for some time.
But this doesn’t change the fact that this week features earnings reports from some of the biggest tech companies in the world, including Amazon (AMZN - Free Report) , Facebook , and the two $1 trillion market cap giants we discuss today.
Apple and Microsoft are both market movers that have soared over the last year. Both companies have also started to expand newer businesses. Apple’s services unit now features everything from its app store to its Netflix (NFLX - Free Report) challenger Apple TV+. Meanwhile, Microsoft has become one of the biggest cloud computing firms.
Apple is set to report its quarterly financial results after the closing bell on Tuesday, with MSFT due out Wednesday. Now the question for investors is what to do with both stocks, as their valuations continue to stretch.
Breakout Biotech Stocks with Triple-Digit Profit PotentialThe biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AMZN - FREE
Get the latest research report on AAPL - FREE
Get the latest research report on MSFT - FREE
Get the latest research report on NFLX - FREE